Merck & Co.
Merck & Co., Inc. is a global healthcare company focused on the discovery, development, and manufacturing of innovative health solutions. The company delivers a diverse portfolio of prescription medicines, biologic therapies, vaccines, and animal health products to address unmet medical needs. Its core value proposition centers on research-driven innovation to treat human disorders and manage the health of livestock and companion animals.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Pharmaceutical
primaryThis segment focuses on human health through the development of therapeutic and preventive agents, including oncology treatments and a broad range of vaccines. It targets a wide array of conditions including cancer, infectious diseases, and cardiometabolic disorders.
Keytruda, Gardasil, Januvia, Winrevair, Bridion, Vaxneuvance, Capvaxive, Welireg, Lagevrio
Drug wholesalers, Retailers, Hospitals, Government agencies, Managed health care providers, Physicians
Animal Health
majorThis segment discovers and markets veterinary pharmaceuticals, vaccines, and health management solutions. It also provides digitally connected identification and monitoring products for both livestock and companion animals.
Bravecto, Nuflor, Bovilis, Sentinel, Allflex Livestock Intelligence, Sure Petcare, Vetsulin, Exzolt
Veterinarians, Distributors, Animal producers, Farmers, Pet owners
Segment Financials
Alliance revenue - Koselugo — Milestone payments
View metricAlliance revenue - Koselugo — Collaborative arrangement, future fixed upfront payments
View metricBusiness Overview
Competitive Position
A leading global research-based biopharmaceutical company with a dominant position in oncology and vaccines, supported by a significant animal health business.
Geographies
United States, European Union, Japan, China, Emerging Markets
Customer Segments
Healthcare Providers, Government Entities, Veterinary Clinics, Agricultural Producers
Upstream Dependencies
Raw material suppliers, Intermediate chemical manufacturers, Academic research institutions, Third-party manufacturing partners
Downstream Customers
Drug wholesalers (e.g., McKesson, AmerisourceBergen), Pharmacy benefit managers, Public health systems, Retail pharmacies, Veterinary distributors
Competitors & Partners
Competitors
Bristol-Myers Squibb
BMY
Direct competitor in oncology (immuno-therapy)
Zoetis
ZTS
Primary competitor in the animal health segment
Pfizer
PFE
Global research-based biopharmaceutical competitor
Johnson & Johnson
JNJ
Competitor in oncology and immunology
Regeneron Pharmaceuticals
REGN
Competitor in oncology (Keytruda) and various therapeutic areas.
United Therapeutics
UTHR
Competitor with Winrevair (sotatercept) for PAH treatment
Revolution Medicines, Inc.
RVMD
Developing KRAS G12C programs
Partners
AstraZeneca
AZN
Global strategic oncology collaboration for Lynparza
Pfizer
PFE
Collaboration on KEYNOTE-A39 and KEYNOTE-905 trials
Moderna
MRNA
Collaboration for individualized neoantigen therapy V940
Gilead Sciences
GILD
Collaboration for HIV-1 treatment combinations
Ridgeback Biotherapeutics LP
Collaboration for Lagevrio (molnupiravir)
Subsidiaries
Allflex Livestock Intelligence
Animal identification and monitoring business unit
Sure Petcare
Companion animal well-being and identification brand
Merck & Co. FAQ
Common questions about Merck & Co.
Merck & Co., Inc. is a global healthcare company focused on the discovery, development, and manufacturing of innovative health solutions. The company delivers a diverse portfolio of prescription medicines, biologic therapies, vaccines, and animal health products to address unmet medical needs. Its core value proposition centers on research-driven innovation to treat human disorders and manage the health of livestock and companion animals.
Merck & Co. (MRK) has a market capitalization of $302.33B and trades on NYSE.
Merck & Co. generated $65.8B in trailing twelve-month revenue with net income of $8.9B, representing a net margin of 13.6%. Gross margin stands at 73.9%, with free cash flow of $14.1B. These figures are based on the Q1 2026 filing.
Merck & Co.'s key competitors include Bristol-Myers Squibb, Zoetis Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.